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Abstract
Background: Poly (ADP-ribose) polymerase inhibitors targeting BRCA1/2 mutations are available for treating patients
with high-grade serous ovarian cancer. These treatments may be more appropriately directed to patients who might
respond if the tumor tissue is additionally tested by next-generation sequencing with a multi-gene panel and Sanger
sequencing of a blood sample. In this study, we compared the results obtained using the next-generation sequencing
multi-gene panel to a known germline BRCA1/2 mutational state determined by conventional Sanger sequencing to
evaluate the landscape of somatic mutations in high-grade serous ovarian cancer tumors.
Methods: Cancer tissue from 98 patients with high-grade serous ovarian cancer who underwent Sanger sequencing
for germline BRCA1/2 analysis were consecutively analyzed for somatic mutations using a next-generation sequencing
170-gene panel.
Results: Twenty-four patients (24.5%) showed overall BRCA1/2 mutations. Seven patients (7.1%) contained only somatic
BRCA1/2 mutations with wild-type germline BRCA1/2, indicating acquired mutation of BRCA1/2. Three patients (3.1%)
showed reversion of germline BRCA1 mutations. Among the 14 patients (14.3%) with both germline and somatic
mutations in BRCA1/2, two patients showed different variations of BRCA1/2 mutations. The next-generation sequencing
panel test for somatic mutation detected other pathogenic variations including RAD51D and ARID1A, which are
possible targets of poly (ADP-ribose) polymerase inhibitors. Compared to conventional Sanger sequencing alone, next-
generation sequencing-based tissue analysis increased the number of candidates for poly (ADP-ribose) polymerase
inhibitor treatment from 17.3% (17/98) to 26.5% (26/98).
Conclusions: Somatic mutation analysis by next-generation sequencing, in addition to germline BRCA1/2 mutation
analysis, should become the standard of care for managing women with high-grade serous ovarian cancer to widen
the indication of poly (ADP-ribose) polymerase inhibitors.
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Background
BRCA1/2 mutational loss of function is a primary driver
of epithelial ovarian cancer and is the basis of therapeu-
tics targeting a synthetic lethality mechanism of poly
(ADP-ribose) polymerase (PARP) inhibition in combin-
ation with BRCA1/2 mutation or possibly other homolo-
gous recombination genetic deficiencies [1, 2].
Most patients evaluated in previous PARP inhibitor-
related randomized trials showed germline BRCA1/2
mutations [3]. However, the results of these studies may
also be applicable to patients with somatic BRCA1/2
mutations [4, 5]. In 2014, the PARP inhibitor olaparib
(Lynparza™, AstraZeneca, Cambridge, UK) was approved
for treating patients with relapsed ovarian cancer with
germline BRCA1/2 mutations by the US Food and Drug
Administration and European Medicines Agency and for
patients with somatic BRCA1/2 mutations by the
European Medicines Agency [6].
In high-grade serous ovarian cancer (HGSOC), which
comprises the majority of epithelial ovarian cancer cases,
germline and somatic mutations in BRCA1/2 are detected
in 17–25% of patients, with somatic mutations represent-
ing 18–30% of all BRCA1/2 mutations [7–9]. Analysis of
ovarian cancer tissue from patients with HGSOC showed
that loss of the normal copy of BRCA1/2 occurs in most
germline BRCA1/2 mutations, indicating that this is an
early event in HGSOC development [10].
In this study, we performed (i) next-generation se-
quencing (NGS) to determine the mutational state of
BRCA1/2 in ovarian cancer tissues from 98 consecutive
patients with HGSOC; (ii) compared the results to the
known germline BRCA1/2 mutational state by conven-
tional Sanger sequencing of blood samples; and (iii) de-
termined the genetic landscape of somatic mutations in
HGSOC tumors.
Methods
Study population
An electronic medical record review of patients treated
for HGSOC at the Department of Obstetrics and
Gynecology at the Severance Hospital of Yonsei University
between January 2017 and February 2019 was carried out.
Ninety-eight patients with HGSOC who were tested for
both germline and somatic BRCA1/2 mutations were in-
cluded in the analysis. The medical record and pedigree of
each patient were reviewed, and data including age at
HGSOC diagnosis, family history of BRCA1/2-related can-
cer, history of primary breast cancer, residual disease after
cytoreductive surgery, and survival status were collected.
A patient was considered to have a family history of
BRCA1/2-related cancer if there were one or more in-
stances of ovarian, peritoneal, fallopian tube, breast, pan-
creas, or prostate cancer among first- or second-degree
relatives. This study was reviewed and approved by our
organization’s institutional review board and was per-
formed in accordance with the ethical standards described
in the Declaration of Helsinki.
Genetic testing for germline BRCA1/2 mutations
All patients underwent in-house testing as previously re-
ported [9]. Briefly, we identified all small base pair varia-
tions by Sanger sequencing on a 3730 DNA Analyzer
with the BigDye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, Foster City, CA, USA). Sequencing
data were aligned against appropriate reference se-
quences and analyzed using Sequencher 5.3 software
(Gene Codes Corp., Ann Arbor, MI, USA).
Genetic testing for somatic mutations using NGS multi-
gene panel
All the tissue used for the NGS analysis was obtained at
the first time of taking cancer tissue, i.e. at the time of
primary debulking surgery or diagnostic laparoscopy.
Formalin-fixed paraffin-embedded (FFPE) sections (5-
μm-thick) were deparaffinized in xylene, hydrated
through graded alcohols to water, and stained with Gill’s
hematoxylin. The slides were manually microdissected
under a dissecting microscope using a scalpel point
dipped in ethanol. The scraped material was washed in
phosphate-buffered saline and digested in proteinase K
overnight at 37 °C in ATL Buffer (Qiagen, Hilden,
Germany). DNA and RNA were then isolated using the
QIAamp DSP DNA FFPE extraction kit (cat # 60404)
and RNeasy FFPE kit (cat # 73504) according to the
manufacturer instructions.
Mutational and copy number analysis was carried out
using the Illumina TST-170 panel, according to the
manufacturer instructions (San Diego, CA, USA). The
gene panels cover 170 cancer-related genes for muta-
tional analysis and 59 genes for copy number analysis
(Supplementary Table 1). For mutational analysis,
FASTQ files were uploaded on Illumina’s BaseSpace
software for variant interpretation. Only variants in cod-
ing regions and promoter regions or splice variants were
retained. In addition, only variants present in < 1% of the
population according to ExAC and 1000 Genomes data-
bases, and which were present in > 5% of reads with a
minimum read depth of 250, were retained. All retained
variants were reviewed using reference websites [Cata-
logue of Somatic Mutations in Cancer (http://evs.gs.
washington.edu/EVS/), Precision Oncology Knowledge
Base (http://oncokb.org), and dbSNP (https://www.ncbi.
nlm.nih.gov/snp)], and only pathogenic variants were se-
lected. In copy number analysis, genes showing greater
than 2-fold change compared to the average level were
considered to have undergone amplification. Genes
showing a lower than 0.7-fold change compared to the
average levels were considered to exhibit significant copy
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number loss. Fusion and splice variants were detected by
RNA analysis workflow in the TST-170 panel. RNA was
converted to cDNA in the first step, and the remaining
steps of NGS library preparation, hybrid-capture based
enrichment, and sequencing were similar to the work-
flow of the DNA analysis module of TST-170 except for
the hybrid-capture probes for 55 genes included in the
RNA analysis workflow. Data analysis for fusion and
splice variants was performed with TST-170 Local App
provided by Illumina. Specifically, Manta was used for
the fusion variant calling. For splice variant calling, Illu-
mina’s RNA Splice Variant Calling software was used.
Statistical analyses
IBM SPSS version 23 for Windows (SPSS Inc., Chicago, IL,
USA) was used for statistical analysis. The Kolmogorov–
Smirnov test was used to validate standard normal distribu-
tion assumptions. Pearson’s chi-square test, Fisher’s exact
test, Student’s t-test and Mann–Whitney U-test were used
for univariate analysis. Survival outcomes were determined
using Kaplan–Meier survival analysis.
Results
Study population
Patient characteristics are shown in Table 1. Of the 98
patients, 46 patients received neoadjuvant chemotherapy
(NAC) after diagnostic laparoscopy. There was no differ-
ence in the proportion of patients who treated with
NAC between the overall BRCA1/2 mutation group and
the BRCA1/2 wild-type group. All the patients receive
platinum-based chemotherapy, and PARP inhibitor was
not used. Patients with overall BRCA1/2 mutations
tended to show a higher rate of BRCA1/2-related family
history and breast cancer history compared to patients
with wild-type BRCA1/2. However, no factors showed a
significant difference. Overall BRCA1/2 mutation ap-
peared to be correlated with a better prognosis than
wild-type BRCA1/2, which was comparable to the results
of our previous study; however, this tendency was not
significant, likely because of the small number of pa-
tients (Fig. 1) [11].
Frequency and spectrum of germline and somatic BRCA1/
2 mutation
Figure 2 shows the distribution of germline and somatic
BRCA1/2 mutations in this population. Twenty-four
(24.5%) of the 98 patients had either germline or somatic
BRCA1/2 mutations. Among the 24 patients with muta-
tions in BRCA1 or BRCA2, 14 showed both germline
and somatic mutations. However, three and seven patients
contained only germline and only somatic mutations, indi-
cating reversion (Reversion #1–3) and acquired mutation
(Acquired #1–#7) of BRCA1/2, respectively (Table 2).
Interestingly, even among the 14 patients who had both
germline and somatic mutations, two showed variations in
BRCA1/2 (Replace #1–#2). The inconsistent BRCA1/2
status is presented in Table 2.
Landscape of somatic mutations shown in NGS multi-
gene panel
The landscape of somatic mutations of the included
patients is shown in Fig. 3. Ten mutated genes were de-
tected in 92 (93.9%) of the 98 patients: TP53, BRCA2,
BRCA1, KRAS, ARID1A, RB1, PIK3CA, STK11, FGFR2,
and RAD51D. Among them, four genes, TP53, BRCA1,
BRCA2, and KRAS, were detected in multiple patients.
TP53 mutation was observed in 90 (91.8%) patients,
including missense mutation (52, 57.8%), frameshift (19,
21.1%), nonsense mutation (16, 17.8%), and in-frame
deletion (3, 3.3%). BRCA1 and BRCA2 mutations were
detected in 11 (11.2%) and 12 (12.2%) patients, respect-
ively. All patients who had BRCA1 or BRCA2 mutations
showed TP53 mutation. KRAS mutation was detected in 5
patients (5.1%). Additionally, BRCA1/2, ARID1A, and
Table 1 Patient characteristics
Overall BRCAm (n = 24) BRCAw
(n = 74)
P
Germline BRCAm (n = 17) Only Somatic BRCAm (n = 7)
Age 53 (42–74) 54 (48–77) 56 (22–78) 0.353
Stage
I 0 0 1 (1.4) 0.838
II 1 (5.9) 0 3 (4.1)
III 7 (41.2) 3 (42.9) 35 (47.3)
IV 9 (52.9) 4 (57.1) 35 (47.3)
Breast cancer 2 (11.8) 0 1 (1.4) 0.084
BRCA-related FHx 4 (23.5) 3 (42.9) 9 (12.2) 0.05
NGR 10 (58.8) 6 (85.7) 42 (56.8) 0.39
NAC 10 (58.8) 4 (57.1) 32 (43.2) 0.242
BRCAm BRCA mutation, BRCAw BRCA wild type, FHx family history, NGR no gross residual disease, NAC neoadjuvant chemotherapy
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RAD51D mutations, which are introduced by homologous
recombination, may be targets of PARP inhibitors [12, 13].
The median depth of NGS sequencing was 880.5 (range,
280–1337). All information on patients enrolled in this
study is presented in Supplementary Table 2.
Somatic mutations were compared to those in 316
patients with serous ovarian cancer from The Cancer
Genome Atlas (Supplement Figure 1). TP53 mutation
was detected in 88% of patients (277 patients), which
was comparable to the value in our data. However,
BRCA1 and BRCA2 were observed in 4% (12 patients)
and 3% of patients (11 patients); these values were con-
siderably smaller than those in our data.
Discussion
Principal findings
In this study, we compared the germline and somatic
BRCA1/2 mutation status of 98 patients with
HGSOC. Twenty-four (24.5%) of the 98 patients had
either germline or somatic BRCA1/2 mutations.
Three of 17 patients (17.6%) showed restored
BRCA1/2 mutation, and seven of 81 patients (8.6%)
exhibited acquired BRCA1/2 mutations. These data
indicate that among the patients who were negative
for germline BRCA1/2 mutation, approximately 10%
may have only somatic BRCA mutations without
germline mutation.
Fig. 1 Comparison of survival between overall BRCA mutation and BRCA wild-type in the Kaplan-Meier curve. BRCAm, BRCA mutation; BRCAw,
BRCA wild-type
Fig. 2 Distribution of germline and somatic BRCA1/2 mutations. Pts, patients
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Results
NGS-based multi-gene panel testing of ovarian cancer
tissue allows for the identification of somatic mutations
that are not detected by blood-based examination and
are often not identified at low allele frequencies by
Sanger sequencing of tumor samples. The tumor assay
used in this study showed that 93.9% (92/98) of patients
with somatically mutated tumors, including TP53,
BRCA1, BRCA2, KRAS, ARID1A, RB1, PIK3CA, STK11,
FGR2, and RAD51D, were not adequately detected by
Sanger sequencing and BRCA1/2 testing of clinical FFPE
sections. Furthermore, the ability to determine the
mutational status of 170 cancer genes simultaneously
provides insight into the co-occurrence patterns of
mutations, additional oncogenic drivers, and intra- or
inter-tumor heterogeneity, and is useful for identifying
homologous recombination and DNA repair genes be-
yond BRCA1/2 which may be involved in the response
to PARP inhibitors. ARID1A and RAD51D mutations
were found in 2 patients, demonstrating that these pa-
tients are possible candidates for PARP inhibitor treat-
ment [12, 13]. Thus, compared to conventional Sanger
sequencing alone, NGS-based tissue analysis increased
the number of candidates for PARP inhibitor treatment
from 17.3% (17/98) to 26.5% (26/98).
TP53 mutation was found in 90 (91.8%) patients. The
overall frequency of TP53 mutation in the 316 patients
from The Cancer Genome Atlas 2011 study was 88.0%
(277/316), which is comparable to our results (Supplement
Figure 1). All patients with BRCA1/2 mutation showed
TP53 mutation, indicating that BRCA1/2 mutation is an
earlier event than TP53 mutation. The correlation between
Table 2 Inconsistent germline and somatic BRCA1/2 variations
Germline BRCA mutation Somatic BRCA mutation
AA variation Sequence variation Mutation type AA variation Sequence variation Mutation type VAF
Replace #1 BRCA2 p.S93Ifs*8 c.276dupA Frameshift BRCA1 p.K654Sfs*47 c.1961delA Frameshift 2.11
BRCA2 p.I605Yfs*9 c.1806delA Frameshift 24.65
Replace #2 BRCA1 p.W1815* c.5445G > A Nonsense BRCA1 p.W1836* c.5508G > A Nonsense 54.33
Reversion #1 BRCA1 p.S308*fs c.922_924delAGCinsT Frameshift –
Reversion #2 BRCA1 c.5467 + 1G > A Intervening sequence –
Reversion #3 BRCA1 c.212 + 1G > T Intervening sequence –
Acquired #1 – BRCA2 p.E1299V c.3896A > T Missense 5.54
Acquired #2 – BRCA1 p.5308Tfs*6 c.923delG Frameshift 54.73
Acquired #3 – BRCA1 p.F1177Cfs*7 c.3530_3540del Frameshift 27.84
Acquired #4 – BRCA1 p.K1183R c.3548A > G Missense 23.74
Acquired #5 – BRCA1 p.K654Sfs’47 c.1961delA Frameshift 2.11
BRCA2 p.I605Yfs’9 c.1806delA Frameshift 24.77
Acquired #6 – BRCA2 p.I605Nfs’11 c.1805_1805insA Frameshift 2.34
Acquired #7 – BRCA1 p.T499Kfs*4 c.1496delC Frameshift 40.87
AA amino acid, VAF variant allele frequency, VOUS variants of uncertain significance
Fig. 3 Landscape of somatic mutations and germline BRCA1/2 mutations in 98 patients with HGSOC. HGSOC, high-grade serous ovarian cancer
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BRCA1/2 and TP53 observed in this study is consistent
with the results of previous studies evaluating patients with
breast cancer [14].
Clinical implications
In the previous study, patients with ovarian cancer who did
not carry germline BRCA1/2 mutations also responded to
PARP inhibitors, suggesting that the broader dysfunction of
genes, such as a homologous recombination-deficient
phenotype, is important [15]. As initially reported in a pre-
vious phase II study of olaparib, objective responses were
confirmed in 41% (7/17) of patients with ovarian cancer
with germline BRCA mutations and 24% (11/46) of patients
without germline mutations [16]. Remarkably, in re-
sponders belonging to the latter group, BRCA1/2 somatic
mutations were detected. Subsequent studies of olaparib
(Study 19) and rucaparib (ARIEL 2 and Study 10) con-
firmed that BRCA-mutated patients derived the most
significant clinical benefit from PARP inhibitor treatment
and showed no differences in responsiveness to PARP in-
hibitors between germline and somatic BRCA-mutated
HGSOC [17–19]. Both BRCA1, located on chromosome 17
(17q21), and BRCA2, on chromosome 13 (13q12.3), are
very large, and exon 11 of both is thought to encode rele-
vant protein domains as mutations in these regions are
highly pathogenic [10, 20]. However, because of the gene
length and domain complexity, pathogenic mutations may
occur anywhere and can be highly variable as well as
depend on ethnicity [21, 22].
Since the introduction of PARP inhibitors as the first
targeted therapy, ovarian cancer diagnosis has involved
not only standard morphological and immunophenotypic
evaluation of cancer samples, but also detailed genotyping
and mutational profiling. Additionally, an understanding of
the mutational status in genes essential for drug sensitivity
and resistance is necessary to ensure effective treatment of
ovarian cancer. As more studies are conducted and targeted
therapeutics become available, genomic analysis for cancer
diagnosis and treatment will benefit a large number of pa-
tients who currently have unmet medical needs.
Research implications
Further studies are required to determine whether the
extent and duration of benefit in patients with germline
and somatic BRCA1/2 mutations are equivalent. Add-
itionally, the appropriate time for obtaining the tumor
tissue for somatic mutational analysis must be deter-
mined. Specifically, whether previously archived FFPE
sections miss patients whose somatic mutations are ac-
quired later in their pathway of cancer should be evalu-
ated. Notably, 100% of germline and 83% of somatic
loss-of-function mutations showed biallelic inactivation
and were predominantly clonal, suggesting that loss of
function of BRCA can occur early in the development of
HGSOC [23]. This finding indicates that retesting for
somatic BRCA1/2 mutations using fresh biopsies at each
relapse may not be informative, although data from
ARIEL 2 showed controversial results regarding this
point [19].
Low-grade serous ovarian cancer (LGSOC) was known
to have a high prevalence of KRAS and BRAF mutations,
but a low prevalence of TP53 mutations [24]. In our
study, five cases showed KRAS mutation. However, three
out of the five patients had simultaneous TP53 muta-
tions as well. Additionally, contrary to the previous re-
port, all the KRAS-mutated patients were diagnosed
with HGSOC, not LGSOC. We hope to be able to report
a further study that investigates the impact of the results
of NGS panel on the conventional histologic diagnosis
reversely, showing how much proportion of the conven-
tional histologic diagnosis would be changed reflecting
the results of NGS.
Strengths and limitations
This is the first study to compare the germline and som-
atic BRCA1/2 mutation status in patients of Asian ethni-
city, which may guide future research of Asian patients
with HGSOC. The current study had some limitations; it
included a small number of patients and was performed
in a single center. Additionally, NGS-based tests were
not conducted as prospective schedules. Therefore, the
timing of tests was variable among patients and the
exact timing of the acquired or reversion of BRCA1/2
mutations could not be investigated. Also, technical
challenges in identifying the mutations in tumors, such
as difficulty in detecting mutation from archival tumor
specimen and issues related with intratumoral hetero-
geneity, might be criticized as limitations of our study.
Additionally, we could not show whether the “replace”
or “reversion” cases really have the function of replaced
or reversed BRCA1/2 protein, respectively.
Conclusions
The effectiveness of PARP inhibitors likely extends be-
yond the treatment of germline BRCA1/2 mutations to
include homologous recombination deficiency in pa-
tients with HGSOC. NGS-based somatic mutation ana-
lysis, as well as germline BRCA1/2 mutation analysis,
should become the standard of care for managing
women with ovarian cancer to widen the indication of
PARP inhibitors.
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